123 related articles for article (PubMed ID: 35649075)
1. Ozone combined with doxorubicin exerts cytotoxic and anticancer effects on Luminal-A subtype human breast cancer cell line.
Karagulle OO; Yurttas AG
Rev Assoc Med Bras (1992); 2022 Apr; 68(4):507-513. PubMed ID: 35649075
[TBL] [Abstract][Full Text] [Related]
2. Synergistic effects of ozone with doxorubicin on the proliferation, apoptosis and metastatic profile of luminal-B type human breast cancer cell line.
Karagülle OO; Yurttaş AG
Tissue Cell; 2023 Dec; 85():102233. PubMed ID: 37866151
[TBL] [Abstract][Full Text] [Related]
3. Ozone Attenuated H9c2 Cell Injury Induced by Doxorubicin.
Xu L; Wang C; Zou Z; Wu Z
J Cardiovasc Pharmacol; 2021 Jul; 78(1):e86-e93. PubMed ID: 33929391
[TBL] [Abstract][Full Text] [Related]
4. In vitro synergistic effect of hesperidin and doxorubicin downregulates epithelial-mesenchymal transition in highly metastatic breast cancer cells.
Amalina ND; Salsabila IA; Zulfin UM; Jenie RI; Meiyanto E
J Egypt Natl Canc Inst; 2023 Mar; 35(1):6. PubMed ID: 36967442
[TBL] [Abstract][Full Text] [Related]
5. Growth factors and chemotherapeutic modulation of breast cancer cells.
Ciftci K; Su J; Trovitch PB
J Pharm Pharmacol; 2003 Aug; 55(8):1135-41. PubMed ID: 12956904
[TBL] [Abstract][Full Text] [Related]
6. Synergistic cytotoxic effects of an extremely low-frequency electromagnetic field with doxorubicin on MCF-7 cell line.
Ramazi S; Salimian M; Allahverdi A; Kianamiri S; Abdolmaleki P
Sci Rep; 2023 May; 13(1):8844. PubMed ID: 37258563
[TBL] [Abstract][Full Text] [Related]
7. Gef gene therapy enhances the therapeutic efficacy of doxorubicin to combat growth of MCF-7 breast cancer cells.
Prados J; Melguizo C; Rama AR; Ortiz R; Segura A; Boulaiz H; Vélez C; Caba O; Ramos JL; Aránega A
Cancer Chemother Pharmacol; 2010 May; 66(1):69-78. PubMed ID: 19771430
[TBL] [Abstract][Full Text] [Related]
8. Synergistic cytotoxicity of red beetroot (Beta vulgaris L.) extract with doxorubicin in human pancreatic, breast and prostate cancer cell lines.
Kapadia GJ; Rao GS; Ramachandran C; Iida A; Suzuki N; Tokuda H
J Complement Integr Med; 2013 Jun; 10():. PubMed ID: 23828331
[TBL] [Abstract][Full Text] [Related]
9. Lupeol synergizes with doxorubicin to induce anti-proliferative and apoptotic effects on breast cancer cells.
Malekinejad F; Kheradmand F; Khadem-Ansari MH; Malekinejad H
Daru; 2022 Jun; 30(1):103-115. PubMed ID: 35113358
[TBL] [Abstract][Full Text] [Related]
10. Doxorubicin and α-Mangostin oppositely affect luminal breast cancer cell stemness evaluated by a new retinaldehyde-dependent ALDH assay in MCF-7 tumor spheroids.
Bissoli I; Muscari C
Biomed Pharmacother; 2020 Apr; 124():109927. PubMed ID: 31982725
[TBL] [Abstract][Full Text] [Related]
11. Sesamin inhibits macrophage-induced vascular endothelial growth factor and matrix metalloproteinase-9 expression and proangiogenic activity in breast cancer cells.
Lee CC; Liu KJ; Wu YC; Lin SJ; Chang CC; Huang TS
Inflammation; 2011 Jun; 34(3):209-21. PubMed ID: 20617373
[TBL] [Abstract][Full Text] [Related]
12. Luteolin attenuates doxorubicin-induced cytotoxicity to MCF-7 human breast cancer cells.
Sato Y; Sasaki N; Saito M; Endo N; Kugawa F; Ueno A
Biol Pharm Bull; 2015; 38(5):703-9. PubMed ID: 25947916
[TBL] [Abstract][Full Text] [Related]
13. A combined treatment TNF-alpha/doxorubicin alleviates the resistance of MCF-7/Adr cells to cytotoxic treatment.
Cao W; Ma SL; Tang J; Shi J; Lu Y
Biochim Biophys Acta; 2006 Feb; 1763(2):182-7. PubMed ID: 16483679
[TBL] [Abstract][Full Text] [Related]
14. Synergistic antitumor effect of TRAIL and doxorubicin on colon cancer cell line SW480.
Xu LH; Deng CS; Zhu YQ; Liu SQ; Liu DZ
World J Gastroenterol; 2003 Jun; 9(6):1241-5. PubMed ID: 12800232
[TBL] [Abstract][Full Text] [Related]
15. [CD44 variant increases the invasive ability of human breast cancer cell line MCF-7 cells].
Fang XJ; Xu WL; Gong JL; Chen C; Fang LL; Chen QY
Zhonghua Zhong Liu Za Zhi; 2010 Jan; 32(1):22-8. PubMed ID: 20211062
[TBL] [Abstract][Full Text] [Related]
16. Effects of Fucoidan and Chemotherapeutic Agent Combinations on Malignant and Non-malignant Breast Cell Lines.
Abudabbus A; Badmus JA; Shalaweh S; Bauer R; Hiss D
Curr Pharm Biotechnol; 2017; 18(9):748-757. PubMed ID: 29141543
[TBL] [Abstract][Full Text] [Related]
17. Anticancer Activity of New Synthetic α-Methylene-δ-Lactones on Two Breast Cancer Cell Lines.
Wyrębska A; Gach K; Lewandowska U; Szewczyk K; Hrabec E; Modranka J; Jakubowski R; Janecki T; Szymański J; Janecka A
Basic Clin Pharmacol Toxicol; 2013 Dec; 113(6):391-400. PubMed ID: 24034139
[TBL] [Abstract][Full Text] [Related]
18. 11a-N-Tosyl-5-deoxi-pterocarpan, LQB-223, a novel compound with potent antineoplastic activity toward breast cancer cells with different phenotypes.
Lemos LG; Nestal de Moraes G; Delbue D; Vasconcelos Fda C; Bernardo PS; Lam EW; Buarque CD; Costa PR; Maia RC
J Cancer Res Clin Oncol; 2016 Oct; 142(10):2119-30. PubMed ID: 27520309
[TBL] [Abstract][Full Text] [Related]
19. Preventing chemoresistance of human breast cancer cell line, MCF-7 with celecoxib.
Chen C; Shen HL; Yang J; Chen QY; Xu WL
J Cancer Res Clin Oncol; 2011 Jan; 137(1):9-17. PubMed ID: 20229271
[TBL] [Abstract][Full Text] [Related]
20. The Synergistic Anticancer Traits of Graphene Oxide Plus Doxorubicin Against BT474 and MCF7 Breast Cancer Stem Cells In Vitro.
Ebrahimi M; Teimouri M; Pooladi M
Appl Biochem Biotechnol; 2021 Nov; 193(11):3586-3601. PubMed ID: 34324153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
